OncoScreen Plus
Targeted and lmmuno Therapy Drug Screening: A One-step Solution

OncoCompass Target
Reliable and Evidence-based ctDNA Testing

OverCMulti-Cancer Detection Blood Test
A Revolution in Multi-Cancer Early Detection

brPROPHET™ Personalized MRD

Testing Empowers Precision Clinical Research


Comprehensive genomic profiling (CGP) panel for cancer patients

OncoScreenTM-WES is a next-generation sequencing (NGS)-based in vitro diagnostic product for the comprehensive genomic profiling (CGP) of formalin-fixed paraffin-embedded (FFPE) and fresh tissue samples as well as white blood cell (WBC) samples from patients with different solid tumors. This test is capable to detect multiple mutation types in the genomic coding regions, such as single nucleotide variant (SNV) and insertion-deletion (InDel) which covering 1,000 hotspot mutations as well as 34 million non-hotspot mutations. It can also detect copy number variance (CNV) of 374 genes and rearrangement/fusion of 21 genes with extended probes coverage in selected intron regions. Additionally, based upon Burning Rock’s in-house database and proprietary algorithms, OncoScreenTM-WES provides comprehensive biomarkers testing with significant performance of the determination of microsatellite instability (MSI) status, tumor mutation burden (TMB), and homologous recombination deficiency (BRIDGEsocre) analysis. OncoScreenTM-WES is designed to provide clinically actionable reference of appropriate treatment for patients and to explore new mechanisms of drug resistance.

Pan-HEMETM   for Hematologic Malignancies

Pan-HEMETM is a comprehensive genomic profiling (CGP) panel for patients with hematologic malignancies. This panel is able to achieve capture-based targeted sequencing of DNA and RNA from the same sample. It can be applied for multiple indications including leukemia (AML/CML/ALL/CLL), lymphoma, multiple myeloma, myelodysplastic syndromes (MDS),myeloproliferative neoplasms (MPN), histiocytic and dendritic cell neoplasms, and so on. At the level of DNA, the test covers 569 genes for single nucleotide mutations (SNV) and insertion/deletion mutations (InDel), 11 genes for fusion, 42 genes for copy number amplification (CNV) and FLT3-ITD identification. At the level of RNA, the test covers 322 genes, and can detect fusions of FLT3-ITD, KMT2A-PTD and so on. Pan-HEMETM test accepts tumor sample types including bone marrow, peripheral blood or formalin-fixed paraffin-embedded (FFPE) tissue; for paired sample, it accepts oral mucosa or hair follicles. Pan-HEMETM is designed to provide clinically reference of diagnostic classification, prognosis, and potential targeting treatment strategies.